Table 1.
Comparison of baseline characteristics between subjects with and without cancer.
| Original population cohort | Matched cohort | |||||
|---|---|---|---|---|---|---|
| Cancer group (n = 20,707) | Non-cancer group (n = 679,594) | Pa | Cancer group (n = 20,707) | Non-cancer group (n = 20,707) | P | |
| Age group, y (%) | <0.0001 | 0.9994 a | ||||
| 19–29 | 847 (4.1) | 187,646 (27.6) | 847 (4.1) | 846 (4.1) | ||
| 30–39 | 2,122 (10.2) | 168,142 (24.7) | 2,122 (10.2) | 2,124 (10.3) | ||
| 40–49 | 4,079 (19.7) | 150,510 (22.1) | 4,079 (19.7) | 4,078 (19.7) | ||
| 50–59 | 4,495 (21.7) | 88,528 (13.0) | 4,495 (21.7) | 4,498 (21.7) | ||
| 60–69 | 4,613 (22.3) | 50,237 (7.4) | 4,613 (22.3) | 4,614 (22.3) | ||
| 70–79 | 3,373 (16.3) | 24,964 (3.7) | 3,373 (16.3) | 3,372 (16.3) | ||
| 80+ | 1,178 (5.7) | 9,567 (1.4) | 1,178 (5.7) | 1,175 (5.7) | ||
| Sex | <0.0001 | >0.9999 b | ||||
| Male, n (%) | 10,575 (51.1) | 335,736 (49.4) | 10,575 (51.1) | 10,575 (51.1) | ||
| COMORBIDITIES†, n (%) | ||||||
| Hypertension | 12,685 (61.3) | 207,021 (30.5) | <0.0001 | 12,685 (61.3) | 12,682 (61.2) | 0.9700 b |
| Diabetes | 13,071 (63.1) | 212,067 (31.2) | <0.0001 | 13,071 (63.1) | 13,068 (63.1) | 0.3719 b |
| Dyslipidemia | 14,738 (71.2) | 306,923 (45.2) | <0.0001 | 14,738 (71.2) | 14,745 (71.2) | 0.0544 b |
| Coronary artery disease | 8,197 (39.6) | 103,625 (15.2) | <0.0001 | 8,197 (39.6) | 8,196 (39.6) | 0.7064 b |
| Heart failure | 2,703 (13.1) | 26,656 (3.9) | <0.0001 | 2,703 (13.1) | 2,703 (13.1) | >0.9999 b |
| Atrial fibrillation | 1,488 (7.2) | 13,937 (2.1) | <0.0001 | 1,488 (7.2) | 1,488 (7.2) | >0.9999 b |
| CONCURRENT MEDICATION‡, n (%) | ||||||
| Anticoagulant | 759 (3.7) | 6,958 (1.0) | <0.0001 | 759 (3.7) | 703 (3.4) | 0.1049 b |
| Antiplatelet agent | 3,427 (16.5) | 42,612 (6.3) | <0.0001 | 3,427 (16.5) | 3,425 (16.5) | 0.4235 b |
| Statin | 7,755 (37.5) | 147,292 (21.7) | <0.0001 | 7,755 (37.5) | 7,752 (37.4) | 0.2150 b |
| CHEMOTHERAPY, n (%) | ||||||
| Ever | 6,211 (30.0) | 6,211 (30.0) | ||||
| Never | 14,496 (70.0) | 14,496 (70.0) | ||||
| Follow-up time, mo | <0.0001 | |||||
| Mean (SD) | 69.7 (27.3) | 82.7 (8.0) | ||||
| Median (min, max) | 84.0 (0.03, 84.00) | 84.0 (0.03, 84.00) | ||||
*Propensity scores were calculated using a multiple logistic regression model that included sex, age, diabetes, dyslipidemia, coronary artery disease, heart failure, atrial fibrillation, and antiplatelet and statin use.
†
Cases that were claimed for the corresponding disease at least once until the event
‡
Cases that were claimed for the corresponding drug more than twice a month until the event.
a
p-value by Bowker's test for symmetry.
b
p-value by conditional logistic regression analysis.